title: Chondrocyte-derived ezrin-like domain containing protein (CDEP), a rho guanine nucleotide exchange factor, is inducible in chondrocytes by parathyroid hormone and cyclic AMP and has transforming activity in NIH3T3 cells.
abstract: OBJECTIVE
  The purpose of this study is to investigate stage- and hormone-dependent expression of chondrocyte-derived ezrin-like domain containing protein (CDEP), a putative guanine nucleotide exchange factor (GEF) for Rho in chondrocytes, and demonstrate the guanine nucleotide exchange activity of this protein in vitro, as well as the transforming activity in NIH3T3 cells.
  
  
  METHODS
  The expression of CDEP mRNA in growth plate chondrocytes in vivo and in vitro was examined by RT-PCR Southern analysis. The guanine nucleotide exchange activity was determined using a recombinant CDEP peptide containing the DH and PH domains in Sf9 cell lysates. The transforming activity was examined using NIH3T3 cells transiently transfected with a truncated CDEP cDNA.
  
  
  RESULTS
  CDEP mRNA was expressed at the highest level in the hypertrophic (terminal) stage of chondrocytes in vivoand in vitro. Parathyroid hormone (PTH) elicited a biphasic increase of CDEP mRNA in chondrocytes. The CDEP mRNA level increased within 1 h, then decreased nearly to the control level at 3 h. Thereafter the mRNA level started to increase at 6 h, reaching a plateau at 24 h. Dibutyryl cyclic AMP had a similar effect on CDEP expression in chondrocytes. The dissociation of [3H]GDP from RhoA was stimulated dose-dependently by Sf9 cell lysates containing the CDEP peptide. Furthermore, transfection of a truncated CDEP cDNA induced focus formation in NIH3T3 cultures.
  
  
  CONCLUSIONS
  CDEP is a novel GEF for Rho family GTPases with the transforming activity. CDEP may play a role in mediating or modulating the action of cAMP-elevating hormones on maturing chondrocytes.
authors.affiliation: Department of Biochemistry, Hiroshima University School of Dentistry, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Koyano
authors.forename: T
authors.initials: T
authors.lastname: Kawamoto
authors.forename: A
authors.initials: A
authors.lastname: Kikuchi
authors.forename: M
authors.initials: M
authors.lastname: Shen
authors.forename: Y
authors.initials: Y
authors.lastname: Kuruta
authors.forename: S
authors.initials: S
authors.lastname: Tsutsumi
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
authors.forename: M
authors.initials: M
authors.lastname: Noshiro
authors.forename: K
authors.initials: K
authors.lastname: Fujii
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
mesh_terms: D000818:Animals; D015139:Blotting, Southern; D002471:Cell Transformation, Neoplastic; D002478:Cells, Cultured; D019902:Chondrocytes / Q000502:physiology*; D000242:Cyclic AMP / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D020662:Guanine Nucleotide Exchange Factors / Q000378:metabolism*; D008297:Male; D051379:Mice; D010281:Parathyroid Hormone / Q000502:physiology*; D010879:Piperazines / Q000378:metabolism*; D011817:Rabbits; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014162:Transfection
chemical_list: C117547:4-cyclohexyl-1-(1,2-diphenylethyl)piperazine; D020662:Guanine Nucleotide Exchange Factors; D010281:Parathyroid Hormone; D010879:Piperazines; D000242:Cyclic AMP